ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Under-Diagnosed Hyperoxalosis in Transplant-Listed Patients

A. Tariq, L. Lakhani, W. Greenspan, S. Alasfar, F. Naqvi, D. Brennan

Nephrology, Johns Hopkins University, Baltimore, MD

Meeting: 2020 American Transplant Congress

Abstract number: B-095

Keywords: Biopsy, Graft survival, Kidney transplantation, Retransplantation

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session B: Kidney Complications: Non-Immune Mediated Late Graft Failure

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • National Trends in Bariatric Surgical Practice for Patients with End-Stage Renal Disease
  • Calcium Oxalate Deposition in Kidney Allografts: Clinical Chracteristics and Outcome

*Purpose: In an era of increasing kidney transplantation (KTx), hyperoxalosis remains an under-recognized cause for allograft failure. Bariatric interventions are significant risk factors for oxalosis, but hyperoxalosis in sleeves and other intestinal surgeries are not well characterized in end stage kidney disease (ESKD). Screening and monitoring for hyperoxalosis in KTx candidates is neither routinely done nor is screening easily accomplished. We investigated the rate of hyperoxalosis and risk factors in transplant-listed ESKD and non-ESKD patients with history of bariatric interventions. We believe that allograft failure from hyperoxalosis may be an emerging national problem.

*Methods: This is a cross-sectional study using registry data from electronic medical records at a single, large transplant institution. Patients were evaluated for KTx between 2010-2015 and measured the serum oxalate level at the time of KTx evaluation as part of their routine care. We classified patients into six categories based on etiology of hyperoxalosis. We calculated the prevalence of hyperoxalosis among these groups and compared demographics, baseline clinical characteristics, and serum oxalate level. Possion regression was used for analysis.

*Results: Across six risk categories, gastric bypass (n=16), sleeve (n=7), lap-band (n=3), Inflammatory Bowel Disease (n=3), colectomy/intestinal bypass (n=3), and cystic fibrosis (n=2), the prevalence of hyperoxalosis was 63%, 100%, 33%, 67%, 50%, and 67%, respectively. Age, sex, race, co-morbidities, history of prior transplantation, and dialysis modality were similar between the groups; however, BMI was significantly highest among post-sleeve gastrectomy patients (p=0.002). There was no difference in mean phosphorus and PTH levels among groups; however, mean calcium level was significantly lower in colectomy/intestinal bypass group (p=0.037). Bariatric sleeves and intestinal surgeries had the largest range of serum oxalate levels. Nephrolithiasis was reported in 100% of colectomy/intestinal bypass, 67% in cystic fibrosis, and 13% in bariatric surgeries (p=0.01). Mean serum oxalate levels were lower in patients on non-calcium-based binders as opposed to calcium-based binder (Figure). ESKD was higher in patients with hyperoxalosis. As a control, there were 3 donors at risk for oxalosis (2 with sleeve and 1 lap-band bypasses) without hyperoxalosis.

*Conclusions: ESKD patients with newer forms of bariatric interventions are at risk of hyperoxalosis and should consider screening for serum oxalate levels prior to KTx.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Tariq A, Lakhani L, Greenspan W, Alasfar S, Naqvi F, Brennan D. Under-Diagnosed Hyperoxalosis in Transplant-Listed Patients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/under-diagnosed-hyperoxalosis-in-transplant-listed-patients/. Accessed February 27, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Penis Transplantation: First U.S. Experience.
      • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
      • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.